COMMUNIQUÉS West-GlobeNewswire

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss
01/07/2025
Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist Sheffield, July 01, 2025 (GLOBE NEWSWIRE) -- UK MHRA Approval Received for First-In-Human Trial of Rincell- [...]
ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application
01/07/2025
FDA 510(k) application submitted to allow marketing of the ARC-EX ® System for home use in the United States CE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European [...]
CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liquidité
01/07/2025
Communiqué de presse CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liquidité Dijon, France 01 juillet 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), la société [...]
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
01/07/2025
RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-approved oral therapies currently exist for this underserved [...]
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
01/07/2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “ Company ”) announces that it will apply to the TSX Venture Exchange (the “ Exchange ”) to amend the terms of [...]
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
01/07/2025
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
01/07/2025
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug [...]
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
01/07/2025
SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
01/07/2025
TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of [...]
Thought Leadership & Innovation Foundation Releases White Paper Showcasing Model for Non-Profit Collaboration to Improve Outcomes for Chronic Disease Communities
30/06/2025
MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- The Thought Leadership & Innovation Foundation (TLI), a nonprofit at the forefront of health innovation, today announced the release of a groundbreaking white paper, A [...]
Avicanna Announces Results of Annual General Meeting
30/06/2025
TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and [...]
Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000
30/06/2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: [...]
Academy Announces Host, Executive Producer and Author Andy Cohen as 2025 FNCE® Closing Keynote Speaker
30/06/2025
CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Food and nutrition experts from around the world will gather in Nashville, Tenn., October 11-14, for the Academy of Nutrition and Dietetics' 2025 Food & Nutrition [...]
TerrAscend Announces Strategic Exit from Michigan Market
30/06/2025
Net Proceeds from divestitures to pay down Company debt Enables concentrated growth and improved profitability in core markets TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend”) (TSX: TSND, OTCQX [...]
Aptose Announces Deferral of Interest Payment
30/06/2025
SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple [...]
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/06/2025
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported [...]
PetVivo Reports Fiscal 2025 Results
30/06/2025
MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative [...]
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
30/06/2025
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct [...]
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
30/06/2025
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]

Pages